The Tencent and Berkshire Hathaway-backed digital bank is seeking to grow its valuation from $30bn in June to over $50m in flotations in the US and Brazil.
Author: Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the Global Venturing Review podcast.
Shoreline hits $140m round
Gilead and BeiGene participated in a round for the immuno-oncology therapeutics developer in a round that came seven months after it raised $43m.
Chipper Cash receives $250m funding transfer
FTX helped Chipper add $150m to a series C round valuing the cross-border payment platform developer at over $2bn.
Everlaw earns $202m in series D round
Alphabet’s CapitalG unit returned for the legal data platform developer’s latest round, which was led by TPG Growth at a $2bn valuation.
GCV Symposium 2021: Fireside Chat – The new era of partnering and investing
Bayer’s Marianne De Backer spoke with GCV’s James Mawson on the latest in the biotech scene.
GCV Symposium 2021: Welcome and introductions – 10th annual GCV Symposium
GCV editor-in-chief James Mawson gave welcoming remarks together with chair Ignacio Gimenez, managing partner of BP Ventures.
Terran takes off with $1.58bn reverse merger
The Lockheed Martin-backed satellite manufacturer is teaming up with Tailwind Two Acquisition Corp to list on the New York Stock Exchange.
Vidio streams $150m capital injection
The Emtek-owned video streaming platform developer received its first external investment, at a post-money valuation of $900m.
RecargaPay tops up series C to $80m
The mobile payment app developer has expanded an Experian-backed round with a $10m extension, taking its total funding to approximately $110m.
Agendia scans for Nasdaq IPO
Norgine, Axa and Debiopharm are in line for exits as the breast cancer diagnostics test provider is aiming to go public to boost research and development and commercial activities.
Cover builds out $60m series B
Existing investor Lennar returned to back the modular homebuilder in a round led by Gigafund, bringing its overall funding to over $71m.
Aculys Pharma accepts SoftBank-led round
SoftBank’s Vision Fund 2 led a $59.7m round which will support Aculys in bringing a sleep disorder medication it has licensed to Japan.
Entrada Therapeutics enters Nasdaq
The Merck & Co and Roche-backed Duchenne muscular dystrophy drug developer has gone public in an upsized IPO sized at approximately $182m.
Aqara turns up $156m in series C funding
China Telecom was among the participants in a round for the smart home device maker which will support international growth and research and development.